Relievant Medsystems enrolled the first patient in INTRACEPT, a Level I prospective randomized clinical trial comparing the Intracept® Procedure to conservative care to treat chronic low back pain.
Intracept Intraosseous Nerve Ablation uses radiofrequency energy to ablate basivertebral nerves, within the vertebral body. Once ablated, the nerves stop transmitting pain signals. The outpatient procedure lasts up to 90 minutes and can yield instant pain relief.
The study will enroll up to 150 patients at up to 20 U.S. centers. This is the second randomized controlled trial for the procedure, following SMART (Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain Trial), which supported the company’s 3Q16 FDA 510(k) clearance. The new trial mimics certain aspects of SMART—such as patient inclusion/exclusion criteria, safety/efficacy enpoints—and will generate outcomes data to support reimbursement.
Source: Relievant MedSystems, Inc.
Relievant Medsystems enrolled the first patient in INTRACEPT, a Level I prospective randomized clinical trial comparing the Intracept® Procedure to conservative care to treat chronic low back pain.
Intracept Intraosseous Nerve Ablation uses radiofrequency energy to ablate basivertebral nerves, within the vertebral body. Once ablated, the...
Relievant Medsystems enrolled the first patient in INTRACEPT, a Level I prospective randomized clinical trial comparing the Intracept® Procedure to conservative care to treat chronic low back pain.
Intracept Intraosseous Nerve Ablation uses radiofrequency energy to ablate basivertebral nerves, within the vertebral body. Once ablated, the nerves stop transmitting pain signals. The outpatient procedure lasts up to 90 minutes and can yield instant pain relief.
The study will enroll up to 150 patients at up to 20 U.S. centers. This is the second randomized controlled trial for the procedure, following SMART (Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain Trial), which supported the company’s 3Q16 FDA 510(k) clearance. The new trial mimics certain aspects of SMART—such as patient inclusion/exclusion criteria, safety/efficacy enpoints—and will generate outcomes data to support reimbursement.
Source: Relievant MedSystems, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.